Teva & Norton v. Cipla: QVAR RediHaler 12-Patent Dispute Dismissed Without Prejudice
Teva Branded Pharmaceutical Products R&D LLC and Norton (Waterford) Limited filed a 12-patent infringement action against Cipla Limited in the District of New Jersey over beclomethasone dipropionate inhalation aerosol technology underlying QVAR RediHaler. The parties jointly sought and obtained a consent order of dismissal without prejudice after 580 days — leaving all patent claims legally unresolved and refiling options open.
Twelve-Patent Inhaler Dispute Ends by Consent, Merits Unresolved
On 16 February 2024, Teva Branded Pharmaceutical Products R&D LLC and Norton (Waterford) Limited filed suit against Cipla Limited in the U.S. District Court for the District of New Jersey, asserting infringement of twelve patents covering beclomethasone dipropionate inhalation aerosol technology — the active pharmaceutical ingredient and delivery platform underlying QVAR RediHaler (40 mcg). The action is consistent with Hatch-Waxman ANDA litigation, in which a branded drug maker asserts its Orange Book-listed patents against a generic filer to trigger a statutory 30-month stay.
On 18 September 2025, the court entered a consent order of dismissal without prejudice upon joint application of all parties — Teva, Norton (Waterford), and both Cipla entities. No merits determination was made. Dismissal without prejudice means the plaintiffs retain the right to refile the same claims in a future action, and no judgment on patent validity or infringement was issued. The consent nature of the order indicates the parties reached an agreement, the terms of which are not disclosed in the public record.
The 580-day duration suggests the dispute progressed through meaningful pretrial activity before resolution, yet the without-prejudice dismissal format typically signals a commercial or licensing resolution rather than litigation fatigue alone. The scale of the assertion — twelve patents spanning multiple application families — indicates Teva and Norton constructed a layered exclusivity strategy around QVAR RediHaler. What drove the final resolution, whether a settlement, licensing arrangement, or market-timing agreement, is not apparent from the public record.
Filing to Dismissed without Prejudice in 580 days
580 days — above the median for ANDA-related pharma patent disputes resolved pre-trial in New Jersey
Consent dismissal without prejudice: what the order means for both parties
Dismissal without prejudice leaves all patent claims legally alive
A dismissal without prejudice does not adjudicate infringement, validity, or enforceability. All twelve asserted patents remain presumptively valid. Teva and Norton retain the full right to refile suit — against Cipla or any other generic filer — on the same patents. This is the procedural outcome most consistent with an underlying commercial resolution that the parties do not wish to expose through a with-prejudice judgment.
No merits ruling issuedTeva and Norton preserve all enforcement options across twelve patents
Because no court found any of the twelve patents invalid or not infringed, Teva and Norton exit the case with their Orange Book exclusivity positions intact. The without-prejudice format means they face no claim-preclusion bar in future litigation. If a confidential resolution was reached, they may also have secured commercial terms — such as a licensed launch date — without conceding patent strength. The patent portfolio covering QVAR RediHaler technology remains a viable enforcement asset.
Portfolio enforceability preservedCipla avoids an adverse judgment but gains no patent certainty
Cipla obtained no declaratory judgment of invalidity or non-infringement. While a dismissal without prejudice removes the immediate litigation burden, Cipla cannot market its beclomethasone dipropionate ANDA product free of patent risk unless it secured a licensed entry date or other commercial terms through the underlying resolution. Any future ANDA approval remains subject to potential refiling of the same claims by Teva and Norton. The absence of a patent carve-out or court ruling leaves Cipla’s FTO position uncertain.
No FTO certainty establishedTwelve-patent inhaler portfolios signal high barriers for generic ICS entry
The layered assertion of twelve patents across device design, formulation, and method-of-use claims around a single inhaled corticosteroid product illustrates the depth of exclusivity strategies in the branded inhaler segment. Generic entrants targeting pressurised metered-dose inhaler (pMDI) or breath-actuated inhaler platforms should anticipate multi-patent Hatch-Waxman actions. The without-prejudice resolution leaves the sector without judicial guidance on the merits of Teva’s inhaler patent claims.
Inhaler sector exclusivity remains contestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLC | Company | Branded pharma R&D entity and Irish manufacturing affiliate — joint holders of 12 QVAR RediHaler patentsSearch in Eureka ↗ |
| Co-Plaintiff | Norton (Waterford) Limited | Individual | Search in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Indian generic pharmaceutical manufacturer seeking U.S. market entry for beclomethasone dipropionate aerosolSearch in Eureka ↗ |
| Plaintiff counsel | AARON P. MAURER | Attorney | Counsel for TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff counsel | AYELET EVRONY | Attorney | Counsel for TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff counsel | Hector Daniel Ruiz | Attorney | Counsel for TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff counsel | Selena Miriam Ellis | Attorney | Counsel for TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff law firm | DEMANT | Law Firm | Representing TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D LLCSearch in Eureka ↗ |
| Defendant counsel | Loly G. Tor | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | Peter Louis Giunta | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | K&L Gates, LLP | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent order of dismissal without prejudice was entered upon joint application of all named parties, including both Cipla entities (Cipla USA, Inc. and Cipla Ltd.) alongside both plaintiffs. The phrasing confirms this was a bilateral, agreed resolution — not a unilateral voluntary dismissal or a court-ordered termination. No findings on infringement, validity, or claim construction were recorded. Because the dismissal is without prejudice, no issue preclusion or claim preclusion attaches to either side, and the legal status of all twelve asserted patents remains unaltered by this proceeding.
US10561808B2 and 11 further patents — QVAR RediHaler beclomethasone dipropionate inhaler technology
The twelve asserted patents span multiple application families filed between 2009 (US12/532762, issuing as US8132712B2) and 2020 (US16/915558, issuing as US11395889B2), reflecting a sustained prosecution campaign covering the QVAR RediHaler platform over more than a decade. The patents collectively address beclomethasone dipropionate inhalation aerosol technology — encompassing the breath-actuated inhaler device architecture, formulation characteristics, and methods of pulmonary drug delivery at the 40 mcg dose strength. The breadth of the families suggests both device-level and formulation-level exclusivity coverage was pursued in parallel.
For the inhaled corticosteroid segment, a twelve-patent Orange Book listing represents a substantial exclusivity wall that any ANDA filer must navigate in full. Competitors developing generic beclomethasone dipropionate inhalation aerosols — or alternative breath-actuated inhaler platforms targeting the same indication — face potential infringement exposure across device design, active ingredient formulation, propellant systems, and use-method claims. The portfolio’s multi-family structure means patent term extensions and paediatric exclusivities may apply to different family members, potentially staggering the expiry landscape and extending effective market exclusivity beyond any single patent’s nominal term.
Should your R&D team run an FTO against QVAR RediHaler’s 12-patent portfolio?
Any company developing a beclomethasone dipropionate inhalation aerosol, a breath-actuated pressurised metered-dose inhaler, or a competing inhaled corticosteroid device platform should treat these twelve patents as a priority FTO target. The asserted portfolio spans device architecture, formulation, and method-of-use claims — meaning a design-around at the device level alone may not defeat formulation or use claims. ANDA filers, 505(b)(2) applicants, and branded developers of next-generation inhaler platforms in the asthma and COPD space are all within the potential enforcement perimeter.
PatSnap Eureka’s FTO Search Agent can map all twelve asserted patent families against your product specifications in a single workflow — identifying claim-by-claim overlap, continuation chains, and related international equivalents across key markets. Eureka’s AI can also flag pending continuation applications from the same families that may not yet appear in the Orange Book, giving your IP and regulatory teams early warning of emerging exclusivity risks before ANDA submission or product launch.
Run a freedom-to-operate analysis on US10561808B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman inhaler patent cases in the District of New Jersey
Explore related Hatch-Waxman patent infringement actions involving inhaled corticosteroid and breath-actuated metered-dose inhaler technology litigated in the District of New Jersey.
What this case signals for the inhaled corticosteroid IP landscape
A twelve-patent Hatch-Waxman assertion resolved by consent — without a merits ruling — has clear implications for generic inhaler strategy.
Multi-patent inhaler portfolios create compounding litigation risk for generics
Teva’s assertion of twelve patents covering QVAR RediHaler — spanning device, formulation, and use — is consistent with a layered exclusivity strategy that forces generic challengers to clear every claim family before launch. IP teams at generic manufacturers targeting breath-actuated inhaler platforms should map all Orange Book-listed patents early in ANDA development to anticipate the full scope of potential litigation exposure.
Without-prejudice consent dismissals may conceal licensing agreements
In Hatch-Waxman litigation, consent dismissals without prejudice frequently accompany confidential settlement or licensing agreements that set an authorised generic launch date. Competitors and market analysts tracking QVAR RediHaler generic competition should monitor Cipla’s ANDA status and any FDA tentative approval timelines, as a licensed launch could follow this resolution without further public disclosure.
TEVA v Cipla — key questions answered
Teva Branded Pharmaceutical Products R&D LLC and Norton (Waterford) Limited asserted twelve U.S. patents in this action: US10561808B2, US8132712B2, US8931476B2, US10792447B2, US10086156B2, US11559637B2, US10022510B2, US10022509B2, US11395889B2, US10695512B2, US11583643B2, and US11395888B2. All twelve relate to beclomethasone dipropionate inhalation aerosol technology underlying QVAR RediHaler (40 mcg).
Dismissal without prejudice means no court ruled on whether Cipla’s ANDA product infringes any of the twelve patents or whether any patent is invalid. Cipla cannot market its product free of patent risk on the basis of this dismissal alone. If the parties reached a confidential licensing or settlement agreement — which the consent nature of the order suggests — Cipla’s market entry would be governed by those private terms, not by any judicial ruling.
The case is consistent with a Hatch-Waxman ANDA infringement action. The parties, product (beclomethasone dipropionate inhalation aerosol, 40 mcg), court (District of New Jersey — a primary Hatch-Waxman forum), and multi-patent assertion pattern all align with standard ANDA litigation. The public record does not explicitly confirm an ANDA filing number, but the structure strongly suggests a Paragraph IV certification context.
Yes. Because the dismissal is without prejudice, neither claim preclusion nor issue preclusion bars Teva and Norton from refiling suit against Cipla on any or all of the twelve asserted patents. If a subsequent ANDA or commercial act by Cipla constitutes a new act of infringement, a fresh action is available. Any confidential settlement terms, however, may privately restrict refiling as a contractual matter.
QVAR RediHaler is Teva’s branded breath-actuated pressurised metered-dose inhaler delivering beclomethasone dipropionate — an inhaled corticosteroid used for asthma maintenance therapy. Breath-actuated inhalers are technically complex drug-device combinations, enabling patent protection across device mechanics, propellant formulation, actuation triggers, dose-counting systems, and methods of use. This multi-dimensional patentability explains why the product supports a twelve-patent Orange Book exclusivity portfolio.
PatSnap Eureka searches patents and litigation data to answer instantly.